WHO Diagnostic Criteria for Systemic Mastocytosis (2016)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۲۰۰ • واحد: ng/mL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include multifocal mast cell infiltrates. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.
Clinical Indication
The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Diagnosis requires: (1 major criterion + 1 minor criterion) OR (3 minor criteria). Major criterion: multifocal mast cell infiltrates ≥15 cells. Minor criteria: (1) atypical morphology ≥25%, (2) KIT mutations, (3) aberrant CD expression, (4) serum tryptase >20 ng/mL.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| multifocal_mast_cell_infiltrates | string | Yes | Multifocal dense infiltrates of mast cells (≥15 mast cells in aggregates) in bone marrow biopsies and/or other extracutaneous organ sections |
| atypical_mast_cell_morphology | string | Yes | ≥25% of mast cells are atypical (type I or II) on bone marrow smears or spindle-shaped in mast cell infiltrates |
| kit_mutation | string | Yes | KIT-activating point mutations at codon 816 (usually D816V) or other critical KIT regions |
| aberrant_cd_expression | string | Yes | Mast cells express CD2 and/or CD25 and/or CD30 (in addition to normal mast cell markers) by flow cytometry or immunohistochemistry |
| serum_tryptase | float | Yes | Baseline serum tryptase concentration in ng/mL (normal <11.4 ng/mL, criterion met if >20 ng/mL in absence of associated myeloid neoplasm)(ng/mL) |
| associated_myeloid_neoplasm | string | Yes | Presence of associated myeloid neoplasm (affects interpretation of serum tryptase criterion) |
Evidence-Based References (EBM)
- Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646. doi: 10.1097/HS9.0000000000000646DOI: 10.1097/HS9.0000000000000646
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544DOI: 10.1182/blood-2016-03-643544
- Valent P, Alin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893DOI: 10.1182/blood-2016-09-731893
- Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(8):1306-1325. doi: 10.1002/ajh.26962DOI: 10.1002/ajh.26962